Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it has received a milestone payment under the terms of its license agreement with partner Takeda based on the achievement of a clinical development milestone for Takeda’s investigational medicine that utilizes Amanitin-based Antibody Drug Conjugate (ATAC) technology licensed from Heidelberg Pharma. With the dosing of the first patient in a Phase I/II clinical trial in patients with solid tumors, a milestone payment to Heidelberg Pharma became due. Financial details were not disclosed.